Ocular Hypertension Treatment Study (OHTS) - Vision Research ...

Ocular Hypertension Treatment Study (OHTS)
Current as of 08/20/10
Peer Reviewed Manuscripts
1. Gordon, MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group: The
Ocular Hypertension Treatment Study: Design and Baseline Description of the Participants.
Arch Ophthalmol 1999; 117:573-583. PMID:10326953.
2. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MA for the Ocular
Hypertension Study Group. Confirmation of Visual Field Abnormalities in the Ocular
Hypertension Treatment Study (OHTS). Arch Ophthalmol 2000; 118:1187-1194.
PMID:10980763.
3. Piltz J, Gross, R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO and the OHTS
Study Group. Contralateral Effect of Topical -Adrenergic Antagonists in Initial One-Eyed
Trials in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2000; 130:441-453.
PMID:11024416.
4. Brandt JD, Beiser JA, Gordon MO, Kass MA and the OHTS Group. Central Corneal
Thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 2001;
108:1779-1788. PMID:11581049.
5. Feuer WJ, Parrish RK, II, Schiffman JC, Anderson DR, Budenz DL, Wells MC, Hess DJ,
Kass MA, Gordon MO, and the OHTS Group. The Ocular Hypertension Treatment Study:
Reproducibility of Cup/Disc Ratio Measurements Over Time at an Optic Disc Reading
Center. Am J Ophthalmol 2002; 133:19-28. PMID:11755836.
6. Johnson CA, Keltner JL, Cello KE, Edwards M, Kass MA, Gordon MO, Budenz DL,
Gaasterland DE, Werner E, and the Ocular Hypertension Treatment Study (OHTS). Baseline
Visual Field Characteristics in the Ocular Hypertension Treatment Study. Ophthalmology
2002; 109:432-437. PMID:11874743.
7. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK,
Wilson MR, Gordon MO for the Ocular Hypertension Treatment Study Group. The Ocular
Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular
Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma.
Arch Ophthalmol 2002; 120:701-713. PMID:12049574.
8. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK,
Miller JP, Parrish RK, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study
Group. The Ocular Hypertension Treatment Study: Baseline Factors That Predict the Onset
of Primary Open-Angle Glaucoma. Arch Ophthalmol 2002; 120:714-720.
PMID:12049575.
9. Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Kass MA, Gordon MO
for the Ocular Hypertension Study Group. Classification of Visual Field Abnormalities in
the Ocular Hypertension Treatment Study. Arch Ophthalmol 2003; 121:643-650.
PMID:12742841.
Page 1

Ocular Hypertension Treatment Study (OHTS)
Current as of 08/20/10
10. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Coleman AL, Piltz-Seymour
JR, Liebmann JM, Cioffi GA, Trick G, Brandt JD, Gordon MO, Kass MA for the Confocal
Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment
Study. Racial Differences in Optic Disc Topography: Baseline Results From the Confocal
Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment
Study. Arch Ophthalmol 2004; 122:22-28. PMID:14718290.
11. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD,
Trick G, Cioffi GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kass MA for the
Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension
Treatment Study. The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the
Ocular Hypertension Treatment Study: Study Design and Baseline Factors. Am J
Ophthalmol 2004; 137:219-227. PMID:14962409.
12. Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA
for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment
Study: Topical Medication Delays or Prevents Primary Open-Angle Glaucoma in African
American individuals. Arch Ophthalmol 2004; 122:813-820. PMID:15197055.
13. Coleman AL, Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment
Study (OHTS) Group. Baseline Risk Factors for the Development of POAG in the Ocular
Hypertension Treatment Study. Am J Ophthalmol 2004; 138(4):684-5. PMID:15488816.
14. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study
(OHTS) Group. Central Corneal Thickness and Measured IOP Response to Topical Ocular
Hypotensive Medication. Am J Ophthalmol 2004; 138:717-22. PMID:15531304.
15. Kass MA, Gordon MO, Kymes SM for the Ocular Hypertension Treatment Study (OHTS)
Group. Incorporating the Results of the Ocular Hypertension Treatment Study Into Clinical
Practice. Letter to Editor. Arch Ophthalmol 2005;123:1021-22. PMID:16009857.
16. Keltner JL, Johnson CA, Levine RA, Fan JJ, Cello KE, Kass MA, Gordon MO for the
Ocular Hypertension Treatment Study Group (OHTS). Normal Visual Field test results
following glaucomatous visual field endpoints in the Ocular Hypertension Treatment Study.
Arch Ophthalmol 2005;123:1201-06. PMCID:1828122.
17. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G,
Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO
for the Confocal Scaning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension
Treatment Study Group. Baseline Topographic Optic Disc Measurements are Associated
with the Development of Primary Open-Angle Glaucoma: The Confocal Scanning Laser
Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch
Ophthalmol 2005;123:1188-97. PMID:16157798.
18. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C,
Vandenbroucke R, Kass MA, Gordon MO, the Ocular Hypertension Treatment Group:
Test-retest Reproducibility of Optic Disk Deterioration Detected From Stereophotographs by
Masked Graders. Am J Ophthalmol 2005;140:762-64. PMID:16226544.
Page 2

Ocular Hypertension Treatment Study (OHTS)
Current as of 08/20/10
19. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the Ocular Hypertension
Treatment Study (OHTS) Group. Management of Ocular Hypertension: A cost-
Effectiveness Approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol
2006;141:997-1008. PMCID:1775049.
20. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA and the Ocular
Hypertension Treatment Study (OHTS) Group. Asymmetries and Visual Field Summaries
as Predictors of Glaucoma in the Ocular Hypertension Treatment Study (OHTS). Invest
Ophthalmol Vis Sci 2006;47:3896-3903. PMCID:1995656.
21. Keltner JL, Johnson CA, Anderson DR, Levine RA, Fan JJ, Cello KE, Quigley HA, Budenz
DL, Parrish II RK, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study
Group. The Association between Glaucomatous Visual Fields and Optic Nerve Head
Features in the OHTS. Ophthalmology 2006;113:1603-12. PMID:16949445.
22. Herman DC, Gordon MO, Beiser JA, Chylack Jr. LT, Lamping KA, Schein OD, Soltau JB,
Kass MA. Topical Ocular Hypotensive Medication and Lens Opacification: Evidence from
the Ocular Hypertension Treatment Study (OHTS). Am J Ophthalmol 2006;142:800-12.
PMCID:1976472.
23. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish II RK, Piltz-Seymour
JR, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group.
Detection and Prognostic Significance of Optic Disc Hemorrhages During the Ocular
Hypertension Treatment Study. Ophthalmology 2006;113:2137-43. PMCID:1995568.
24. The Ocular Hypertension Treatment Study (OHTS) Group and the European Glaucoma
Prevention Study (EGPS) Group. A Validated Prediction Model for the Development of
Primary Open-Angle Glaucoma in Individuals with Ocular Hypertension. Ophthalmology
2007;114:10-19. PMCID:1995665.
25. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA and
the Ocular Hypertension Treatment Study (OHTS) Group. Comparison of Initial Intraocular
Pressure Response to Topical Beta-Adrenergic Antagonists and Prostaglandin Analogues in
African Americans and Whites in the Ocular Hypertension Treatment Study (OHTS). Arch
Ophthalmol 2007;125:454-9. PMID:17420364.
26. Keltner JL, Johnson CA, Cello KE, Bandermann SE, Fan JJ, Levine RA, Kass MA, Gordon
MO and the Ocular Hypertension Treatment Study (OHTS) Group. Visual Field Quality
Control in the Ocular Hypertenstion Treatment Study (OHTS). J Glaucoma 2007;16:665-9.
PMID:18091452.
27. Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group. Is a
History of Diabetes Mellitus Protective Against Developing Primary Open-Angle
Glaucoma? Arch Ophthalmol 2008;126:280-1. PMID:18268230.
Page 3

Ocular Hypertension Treatment Study (OHTS)
Current as of 08/20/10
28. Kass MA, Gordon MO, for the Ocular Hypertension Treatment Study Group. Diabetes and
Glaucome. Arch Ophthalmol, 2008;126(5):746-7. PMID:18474807.
29. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA and the Ocular
Hypertension Treatment Study Group. Changes in Central Corneal Thickness Over Time:
The Ocular Hypertension Treatment Study. Ophthalmology 2008;115:1550-1556.
PMID:18378313.
30. Ocular Hypertension Treatment Study Group and the European Glaucoma Prevention Study
Group. The Accuracy and Clinical Application of Predictive Models for Primary Open-
Angle Glaucoma in Ocular Hypertensive Individuals. Ophthalmology 2008;115(11):2030-6.
PMID: 18801578
31. Bhorade AM, Gordon MO, Wilson B, Weinreb RN, Kass MA and the Ocular Hypertension
Treatment Study Group. Variability of Intraocular Pressure Measurements in Observation
Participants in the Ocular Hypertension Treatment Study. Ophthalmology 2009;116:717-
724. NIHMS ID:159280.
32. Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK,
Miller JP, Parrish RK, Wilson MR, and the Ocular Hypertension Treatment Study (OHTS)
Group. Delaying Treatment of Ocular Hypertension. Archives of Ophthalmology 2010;
128(3):276-287. PMID: 20212196.
33. Barnett EM, Fantin A, Wilson BS, et al. The Incidence of Retinal Vein Occlusion in the
Ocular Hypertension Treatment Study. Ophthalmology 2010;117(3):484-8. PMID:
20031222.
34. Kymes SM, Plotzke MR, Kass MA, Boland MV, Gordon MO. Effect of Patient’s Life
Expectancy on the Cost-Effectiveness of Treatment for Ocular Hypertension. Arch
Ophthalmol 2010;128(5):613-8. PMID: 20457984.
35. Bhorade AM, Wilson BS, Gordon MO, Palmberg P, Weinreb RN, Miller E, Chang RT,
Kass MA. The Utility of the Monocular Trial: Data from the Ocular Hypertension Treatment
Study, Ophthalmology 2009;116(4):717-724. PMCID: PMC2790916
Published Abstracts and Papers
1. Wong KF, Achtenberg JF, Gordon MO, and the Ocular Hypertension Treatment Study
(OHTS) Group: Automated Forms Processing: Trials, Tribulations and Triumphs.
Controlled Clinical Trials 1994;15:3S, p. 76S.
2. Gordon MO, Li Z, Schechtman KB, Kass MA, and the Ocular Hypertension Treatment
Study (OHTS) Group: Minimizing Variability and Regression to the Mean in IOP
Measurements. Invest Ophthalmol Vis. Sci 1995;36:4, p S81.
Page 4

Ocular Hypertension Treatment Study (OHTS)
Current as of 08/20/10
3. Wong KF, Gordon MO, Achtenberg JF, and the Ocular Hypertension Treatment Study
(OHTS) Group: Electronic Document Archival for a Data Coordinating Center. Controlled
Clinical Trials 1995;16:3S, p. 38S.
4. Gordon MO, Schechtman KB, Li Z, Kass MA, and the Ocular Hypertension Treatment
Study (OHTS) Group: A Protocol to Minimize Bias and Regression to the Mean in
Measurement of Intraocular Pressure. Controlled Clinical Trials 1995;16:3S, p. 98S.
5. Gordon MO, Johnson CA, Spurr JO, Kass MA, and the Ocular Hypertension Treatment
Study (OHTS) Group: Pluses and Minuses of Relaxing Fixation Loss Criterion. Invest
Ophthalmol Vis. Sci 1996;37:3, p S507.
6. Wong K, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: An
inexpensive electronic system for handling adverse event reports. Controlled Clinical
Trials 1996;17:2S.
7. Wong K, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group:
Automatic forms processing with Windows 95: Hyperpole? Controlled Clinical Trials
1996; 17:2S.
8. Wong K, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group:
Electronic systems for handling adverse event reports. Controlled Clinical Trials 1997;
18(3S):145S.
9. Bennett GR, Cioffi GA, Dorr D, Gordon MO, Beck A, Fechtner R, Kass M, and the Ocular
Hypertension Treatment Study (OHTS) Group: Racial differences in response to glaucoma
medications in ocular hypertensive patients. Invest Ophthalmol Vis Sci 1997;38(3):S278.
10. Gross R, Piltz J, Shin DH, Kass MA, Gordon MO, and the Ocular Hypertension Treatment
Study (OHTS) Group: Contralateral effect of topical beta-blockers on intraocular pressure
in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci
1997;38(4):S1056.
11. Dorr D, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group:
Graphically conquering the SF-36: A tool for illustrating subscale by group over time using
SAS/GRAPH Software. Proceedings of the twenty-third Annual SAS Users Group
International Conference 1998;856-859.
12. Keltner JL, Johnson CA, Spurr JO, Kass MA, Gordon MO and the Ocular Hypertension
Treatment Study (OHTS) Group: Confirmation of visual field abnormalities in the Ocular
Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 1998;39(4):S493.
13. Gordon MO, Kass MA, Heuer D, Higginbotham E, Parrish R and the Ocular Hypertension
Treatment Study (OHTS) Group: Baseline demographics and clinical characteristics of
patients enrolled in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci
1998;39(4):S878.
14. Morris PA, Wilder AK, Gordon MO and the Ocular Hypertension Treatment Study
(OHTS) Group: Site visit strategies to increase collaboration of the clinic, resource centers
and coordinating center. Controlled Clinical Trials 1998;19(3S):51S.
Page 5

Ocular Hypertension Treatment Study (OHTS)
Current as of 08/20/10
15. Dorr DA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: A
simple graphical method for displaying multiple dimensions by group over time: and
example using the SF-36. Controlled Clinical Trials 1998;19(3S):72S.
16. Fischbach E, Achtenberg J, Clark K, Tourville D, Gordon MO and the Ocular Hypertension
Treatment Study (OHTS) Group: (Under) Estimating paper storage requirements for a
multicenter clinical trial. Controlled Clinical Trials 1998;19(3S):84S.
17. Bednarski M, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS) and the
Collaborative Longitudinal Evaluation of Keratoconus Study (CLEK) Groups: A quick and
dirty method for delivering SAS reports via the world wide web. MWSUG Conference
Proceedings 1998;405-410.
18. Bednarski MA, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS)
Group: Delivering coordinating center reports to clinics via the world wide web.
Controlled Clinical Trials 1999;20(2S):60S.
19. Wilder AK, Morris PA, Gordon MO and the Ocular Hypertension Treatment Study
(OHTS) Group: Offering continuation education credits at clinic coordinating meeting.
Controlled Clinical Trials 1999;20(2S):67S.
20. Morris PA, Wilder AK, Bednarski MA, Gordon MO and the Ocular Hypertension
Treatment Study (OHTS) Group: Accessing SAS reports by the central coordinators via
the world wide web. Controlled Clinical Trials 1999;20(2S):68S.
21. Feuer WJ, Parrish RK, Wells MC, Schiffman JC, Kass MA, Gordon MO and the Ocular
Hypertension Treatment Study (OHTS) Group: Reproducibility of reading of optic disc
cup/disc ratio in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis
Sci 1999;40(4):S283.
22. Keltner JL, Johnson CA, Spurr JO, Kass MA, Gordon MO and the Ocular Hypertension
Treatment Study (OHTS) Group: Classification of visual field abnormalities in the Ocular
Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 1999;40(4):S69.
23. Keltner JL, Johnson CA, Cello KE, Quigg JM, Kass MA, Gordon MO and the OHTS
group. Severity of the types of visual field abnormalities in the Ocular Hypertension
Treatment Study (OHTS). Invest Opthalmol Vis Sci 2000;41(4):S84.
24. Long E, Dunn D, Gordon M, Ocular Hypertension Treatment Study (OHTS) Group. A
publications and presentation policy for a multicenter clinical trial. Control Clin Trial
2000;21(2S):77S.
25. Randant D, Long E, Gordon M, the Ocular Hypertension Treatment Study (OHTS) Group.
Handling forms in a multicenter clinical trial. Control Clin Trial 2000;21(2S): 100S.
26. Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, Bandermann SE, Edwards MA,
Ocular Hypertension Study Group. Visual field technician performance in the Ocular
Hypertension Treatment Study (OHTS). Invest Opthalmol Vis Sci 2001;42(4): S152.
Page 6

Ocular Hypertension Treatment Study (OHTS)
Current as of 08/20/10
27. Brandt JD, Beiser J, Kass MA, Gordon MO, for the OHTS Study Group. The relationship
of corneal thickness and IOP response to topical β-blocker in the Ocular Hypertension
Treatment Study. Invest Opthalmol Vis Sci 2001; 42(4): S421.
28. Wilder AK, Morris PA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS
) Group. Improving timeliness of annual IRB approvals. Control Clin Trial 2001;22(2S):
79S
29. Bednarski MA, Beiser JA, Gordon MA, Morris PA, Wilder AK, and the Ocular
Hypertension Study (OHTS) Group. Providing performance reports to clinics via the world
wide web. Control Clin Trial 2001;22(2S): 80S.
30. Morris PA, Wilder AK, Bednarski M, Gordon MO, and the Ocular Hypertension Treatment
Study Group. Omnibus clinic tracking report. Control Clin Trial 2001;22(2S):83S.
31. Bednarksi MA, Clark KA, Hornbeck EM, Gordon MO. Dynamic data retrieval using
SAS/IntrNet. SAS Users Group International 2002; paper 197.
32. Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the Ocular Hypertension Study
Group. Viewing case report forms on the web without scanning data. Control Clin Trial
2002;23 (2S):40S.
33. Heuer DK, Higginbotham EJ, Kass MA, Parrish RK, Beiser JA, Gordon MO and the
Ocular Hypertension Treatment Study Group. Is there a penalty for delayed treatment in
ocular hypertensives? Evidence from the Ocular Hypertension Treatment Study (OHTS).
Presented at ARVO, May 4-9, 2003.
34. Achtenberg JF, Hornbeck EM, Gordon MO and the Ocular Hypertension Treatment Study
Group. Enhanced documentation of case report forms. Control Clin Trial
2003;24(3S):180S.
35. Bednarski MA, Achtenberg JF, Gordon MO and the Ocular Hypertension Treatment Study
Group. Tracking and reporting multi-stage processes in a clinical trial. Control Clin Trial
2003;24(3S):187S.
36. Kymes SM, Gordon MO and the Ocular Hypertension Treatment Study Group. Economic
evaluation in clinical trial – a promise half met? Control Clin Trials 2003;24(3S):187S.
37. Morris, PA, Wilder AK, Gordon, MO and the Ocular Hypertension Treatment Study
Group. Encouraging participation after protocol change. Control Clin Trials
2003;23(3S):214S.
38. Keltner JL, Johnson CA, Fan J, Cello KE, Kass MA, Gordon MO and the Ocular
Hypertension Treatment Study (OHTS). Types of visual field abnormalities that
subsequently become visual field primary open-angle glaucoma in the Ocular Hypertension
Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2004;45:E-Abstract 2134. Presented
at ARVO.
Page 7

Ocular Hypertension Treatment Study (OHTS)
Current as of 08/20/10
39. Coleman AL, Gordon MO, Beiser JA, Kass MA and the Ocular Hypertension Treatment
Study. A predictive model for the development of POAG in the Ocular Hypertension
Treatment Study excluding pattern standard deviation(PSD) and vertical cup/disc ratio
(VC/D). Invest Ophthalmol Vis Sci 2004;45:E-Abstract 955. Presented at ARVO.
40. Budenz DL, Beiser JA, Piltz JR, Parrish RK, Anderson DR, Gordon MO, Kass MA and the
Ocular Hypertension Treatment Study Group. Detection and predictive value of optic disc
hemorrhages in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci
2004;45:E-Abstract 940. Presented at ARVO.
41. Beiser JA, Hornbeck E, Morrison D, Gordon MO, Goldberg J. De-identification of shared
datasets. Clinical Trials 2004:1(1S):274.
42. Mansberger SL, Hughes BA, Gordon MO, Spaner SL, Beiser, JA, Cioffi GA, Kass MA and
the Ocular Hypertension Treatment Study (OHTS) Group. Comparison of IOP response to
topical beta-adrenergic antagonists and prostaglandin analogues in African Americans and
whites: The Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci
2005;46: E-Abstract 2449. Presented at ARVO.
43. Keltner JL, Johnson CA, Cello KE, Fan J, Bandermann SE, Kass MA, Gordon MO, Beck
RW and the Ocular Hypertension Treatment Study (OHTS) group. Visual field quality
control in the Ocular Hypertenstion Treatment Study and in the 10-Year Optic Neuritis
Treatment Trial (ONTT) Follow-Up Study. Invest Ophthalmol Vis Sci 2005;46: E-
Abstract 3738. Presented at ARVO.
44. Kass MA, Beiser JA, Herman D, Lamping K, Soltau J, Gordon MO and the Ocular
Hypertension Treatment Study Group. Is there an association of topical ocular hypotensive
medication with lens opacification and visual function?: Evidence from the Ocular
Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2005; 46: E-Abstract 2448.
Presented at ARVO.
45. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz MC,
Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Test-retest
reproducibility of determining optic disc deterioration in the Ocular Hypertension
Treatment Study (OHTS). Invest Ophthal Vis Sci 2005;46: E-Abstract 3630. Presented at
ARVO.
46. Zangwill LM, Weinreb RN, Beiser JA, Cioffi GA, Coleman AL, Trick G, Liebmann JM,
Kass MA, Gordon MO and the OHTS CSLO Ancillary Study Group. Baseline topographic
optic disc measurements are associated with the development of primary open angle
glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the OHTS.
Invest Ophthal Vis Sci 46: E-Abstract 3631. Presented at ARVO May 1-6, 2005.
47. Keltner JL, Johnson CA, Cello KE, Fan J, Levine RA, Bandermann SE, Kass MA, Gordon
MO, Beck RW and the Ocular Hypertension Treatment Study Group. Visual Field
Quality Control in the Ocular Hypertension Treatment Study (OHTS) and the Optic
Neuritis Treatment Trial (ONTT). Invest Ophthal Vis Sci 2006; E-Abstract 3394.
Presented at ARVO.
Page 8

Ocular Hypertension Treatment Study (OHTS)
Current as of 08/20/10
48. Brandt JD, Beiser JA, Gordon MO, Lin SC , Alexander MY, Kass MA and the Ocular
Hypertension Treatment Study Group. Time Dependent Changes in Central Corneal
Thickness in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci
2006; E-Abstract 4422. Presented at ARVO.
49. Morris PA, Roediger T, Achtenberg J, Bednarski M, Clark K, Hornbeck B, Gordon MO
and the Ocular Hypertension Treatment Study (OHTS) Group. Certification,training, and
support of a web-based data entry system. Clinical Trials 2006; 3:191-247. Presented at
SCT.
50. Clark KA, Bednarski MA, Gordon MO and the Ocular Hypertension Treatment Study
(OHTS). Integrating adverse event data into a web-based data management. Clinical Trials
2006; 3:191-247. Presented at SCT.
51. Bandermann SE, Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, and Ocular
Hypertension Treatment Study Group. A Comparison Of Full Threshold and Swedish
Interactive Threshold Algorithms (SITA) Testing procedures in the Ocular Hypertension
Treatment Study (OHTS). Invest Ophthal Vis Sci 2007;E-Abstract 1643. Presented at
ARVO.
52. Artes PH, Chauhan BC, Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, and
Ocular Hypertension Treatment Study Group. Longitudinal and Cross-Sectional Analyses
of Visual Field Progression in the Ocular Hypertension Treatment Study (OHTS). Invest
Ophthal Vis Sci 2007;E-Abstract 4447. Presented at ARVO.
53. Bhorade AM, Wilson BS, Palmberg P, Miller E, Chang RT, Kass MA,Gordon
MO,andOcular Hypertension Treatment Study Group. The Predictive Accuracy of the One-
Eyed Trial in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci
2007; E-Abstract 5555. Presented at ARVO.
54. Achtenberg JF, Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the Ocular
Hypertension Treatment Study Group. Phased transition from traditional data entry to a
web-based system. Presented at SCT May 21-24,2007.
55. Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Is a history
of diabetes mellitus (DM) protective against developing primary open-angle glaucoma
(POAG)? Presented at the American Glaucoma Society, March 7, 2008.
56. Keltner JL, Johnson CA, Cello KE, Brusini P, Kass MA, Gordon MO and the Ocular
Hypertension Treatment Study Group. Application of Brusini’s Glaucoma Staging System
2 (GSS 2) to glaucomatous visual fields in the Ocular Hypertension Treatment Study.
Presented at ARVO, April 27, 2008.
57. Bhorade AM, Wilson BS, Palmberg P, Miller E, Weinreb R, Kass MA, Gordon MO and
the Ocular Hypertension Treatment Study Group. Intraocular pressure variability in
observation participants in the Ocular Hypertension Treatment Study. Presented at ARVO,
April 28, 2008.
58. Kymes SM, Kass MA, Miller JP, Gordon MO, and the Ocular Hypertension Treatment
Study Group. The 20-year incidence of primary open-angle glaucoma among people with
ocular hypertension – A decision analytic approach. Presented at ARVO, May 1, 2008.
Page 9

Ocular Hypertension Treatment Study (OHTS)
Current as of 08/20/10
59. Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO and the Ocular Hypertension
Treatment Study Group. Retinal vein occlusions (RVO) in the Ocular Hypertension
Treatment Study. Presented at ARVO, May 1, 2008.
60. Long EF, Dunn D, Gordon MO, the Ocular Hypertension Treatment Study group. Closeout
manual of procedures for a long-term clinical trial. Presented at the Society for Clinical
Trials. May 19, 2008.
61. Gordon MO, Sarli C, Long EF, LaRue C, the Ocular Hypertension Treatment Study Group.
Assessing the impact of research. Presented at the Society for Clinical Trials, May 20,
2008.
62. Kass MA, Gordon MO, the Ocular Hypertension Treatment Study Group. Diabetes and
Glaucoma. Arch Ophthalmol. 2008;126(5):746-747.
63. Gordon MO. Impact of attributing cause of abnormality to POAG on endpoint rate and
statistical power in the OHTS. Presented at ARVO, May 2, 2010.
64. Gordon MO, Heuer DK, Higginbotham EJ, Parrish RK, Morris PA, Dunn DA, Wilson BS,
Kass MA, the Ocular Hypertension Treatment Study Group. Impact of attributing cause of
abnormality to POAG on endpoint rate and statistical power in the OHTS. Presented at
ARVO, May 2, 2010.
65. Kass MA. Incidence of glaucomatous visual field loss subsequent to initial glaucomatous
optic disc deterioration in the OHTS. Presented at ARVO, May 3, 2010.
66. Zangwill L. The rate of topographic optic disc change is faster in eyes developing POAG
than in eyes not developing POAG: CSLO Ancilliary Study to the OHTS. Presented at
ARVO, May 3, 2010.
67. DeMoraes C. Effect of treatment on rates of visual field change in the OHTS. Presented at
ARVO, May 3, 2010.
68. Brandt JD. Does Adjusting IOP for central corneal thickness improve accuracy of the
prediction model for the development of POAG? Presented at ARVO, May 4, 2010.
69. Demirel S. Rates of change of mean deviation in the OHTS. Presented at ARVO, May 6,
2010.
Page 10